Amexdrug Corporation
AXRX
$0.0021
$0.00015.00%
| Weiss Ratings | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.25 | |||
| Price History | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 5.00% | |||
| 60-Day Total Return | 5.00% | |||
| 90-Day Total Return | 90.91% | |||
| Year to Date Total Return | 5.00% | |||
| 1-Year Total Return | 600.00% | |||
| 2-Year Total Return | -98.98% | |||
| 3-Year Total Return | -98.38% | |||
| 5-Year Total Return | -98.19% | |||
| 52-Week High % Change | -16.00% | |||
| 52-Week Low % Change | 110.00% | |||
| Price | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Jun 12, 2023 | |||
| 52-Week High Price (Date) | May 16, 2023 | |||
| Valuation | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 355.13K | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | 2.33 | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.04 | |||
| Price/Book (Q) | 0.54 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 169.41M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 323-725-3100 | |||
| Address | 7251 Condor Street Commerce, CA 90040 | |||
| Website | www.amexdrug.com | |||
| Country | United States | |||
| Year Founded | 1963 | |||
| Profitability | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 3.61% | |||
| Profit Margin | 1.80% | |||
| Management Effectiveness | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 11.25% | |||
| Return on Equity | 28.80% | |||
| Income Statement | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 9.17M | |||
| Total Revenue (TTM) | 9.17M | |||
| Revenue Per Share | $0.05 | |||
| Gross Profit (TTM) | 1.26M | |||
| EBITDA (TTM) | 380.80K | |||
| EBIT (TTM) | 331.00K | |||
| Net Income (TTM) | 165.90K | |||
| Net Income Avl. to Common (TTM) | 165.90K | |||
| Total Revenue Growth (Q YOY) | -6.96% | |||
| Earnings Growth (Q YOY) | 36.88% | |||
| EPS Diluted (TTM) | 0.00 | |||
| EPS Diluted Growth (Q YOY) | 50.00% | |||
| Balance Sheet | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 168.00K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 1.78M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 658.20K | |||
| Current Ratio (Q) | 1.345 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 2.28M | |||
| Total Current Liabilities (Q) | 1.32M | |||
| Total Debt (Q) | 961.10K | |||
| Total Liabilities (Q) | 1.63M | |||
| Total Common Equity (Q) | 658.20K | |||
| Cash Flow | AXRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -459.30K | |||
| Cash from Financing (TTM) | 593.30K | |||
| Net Change in Cash (TTM) | 59.20K | |||
| Levered Free Cash Flow (TTM) | -529.40K | |||
| Cash from Operations (TTM) | -74.90K | |||
